Technical Analysis for CMPX - Compass Therapeutics, Inc.

Grade Last Price % Change Price Change
C 3.0 4.17% 0.12
CMPX closed up 4.17 percent on Tuesday, December 7, 2021, on 23 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical CMPX trend table...

Date Alert Name Type % Chg
Hot IPO Pullback Bullish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
New 52 Week Closing Low Bearish 4.17%
Hot IPO Pullback Bullish Swing Setup 4.17%
Wide Bands Range Expansion 4.17%
Below Lower BB Weakness 4.17%
Lower Bollinger Band Touch Weakness 4.17%
Bearish Engulfing Bearish -7.41%
Older End-of-Day Signals for CMPX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% 1 day ago
Down 3% 1 day ago
Fell Below Previous Day's Low 1 day ago
Down 2 % 1 day ago
Down 1% 1 day ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Compass Therapeutics, Inc. Description

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Its scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company's pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment; and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Immune System Antibodies Oncology Tumor Tumors Human Diseases Immune Checkpoint Tumor Microenvironment Angiogenesis Oncology Focused Biopharmaceutical

Is CMPX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.38
52 Week Low 2.66
Average Volume 302,883
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 3.44
10-Day Moving Average 3.22
Average True Range 0.45
ADX 0.0
+DI 14.29
-DI 17.17
Chandelier Exit (Long, 3 ATRs) 2.74
Chandelier Exit (Short, 3 ATRs) 4.01
Upper Bollinger Bands 4.01
Lower Bollinger Band 2.86
Percent B (%b) 0.12
BandWidth 33.72
MACD Line -0.21
MACD Signal Line -0.14
MACD Histogram -0.0714
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.51
Resistance 3 (R3) 3.54 3.39 3.43
Resistance 2 (R2) 3.39 3.26 3.38 3.40
Resistance 1 (R1) 3.20 3.18 3.30 3.17 3.37
Pivot Point 3.05 3.05 3.10 3.04 3.05
Support 1 (S1) 2.86 2.92 2.96 2.83 2.63
Support 2 (S2) 2.71 2.84 2.70 2.60
Support 3 (S3) 2.52 2.71 2.58
Support 4 (S4) 2.49